ReviewTherapeutic advances in hematology2021

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.

Foteini Theodorakakou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.